Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated claim matches the FDA label’s Indications and Usage and the requirement to use JAVYGTOR with a Phe-restricted diet; no contradictions, unsupported additions, or relevant omissions were identified.
Category Scores
Accurate Statements
The provided FDA label supports that JAVYGTOR (sapropterin dihydrochloride) reduces blood phenylalanine (Phe) levels in adult and pediatric patients (≥1 month) with hyperphenylalaninemia due to BH4-responsive PKU, when used in conjunction with a Phe-restricted diet.
Indications and Usage: reduces blood Phe levels in adults and pediatric patients one month of age and older with HPA due to BH4-responsive PKU; JAVYGTOR is to be used in conjunction with a Phe-restricted diet. Also supported by 2.1 that patients must also be treated with a Phe-restricted diet.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim is limited to labeled indication/expected effect and concomitant diet requirement; it does not add dosing, contraindications, or safety guidance beyond what is supported.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement